The use of selective cyclooxygenase‐2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada
Authors:
- Jaume AguadoJAJaume Aguado
- Luis Alberto García RodriguezLRLuis Alberto García Rodriguez
- 28 August 2009
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 18 (11) , 1016-1025
Abstract
Background: Meta‐analyses of observational studies show variability in the risk of acute myocardial infarction (AMI) among non‐steroidal anti‐inflammatory drugs (NSAIDs), with an increase in risk for rofecoxib and diclofenac, and no increase in risk for celecoxib, naproxen, or ibuprofen.Methods and Results: We identified a cohort of 364 658 individuals aged 40–84 years who were enrolled in Saskatchewan Health, Canada, from 15 November 1999 to 31 December 2001. A nested case–control analysis compared 3252 incident cases of hospitalized AMI and out‐of‐hospital CHD deaths with 20 002 controls randomly sampled from the cohort. The incidence of AMI/CHD was 5.1 per 1000 person‐years (95%CI: 5.0–5.3). The adjusted ORs (95%CI) of AMI/CHD in current users of individual NSAIDs compared with non‐use were: celecoxib (1.11; 0.84–1.47), rofecoxib (1.32; 0.91–1.91), diclofenac (1.02; 0.75–1.38), naproxen (1.57; 0.98–2.52), ibuprofen (1.59; 0.88–2.89), and indomethacin (1.34; 0.81–2.19). Long‐term use of rofecoxib was compatible with an increased risk (OR = 1.46; 0.97–2.22) while estimates of other individual NSAIDs were close to unity. Overall NSAID use was associated with a 30% increased risk of nonfatal AMI but was absent for fatal AMI/CHD.Conclusions: This study showed a modest increased risk of AMI/CHD with various traditional NSAIDs and COX‐2 inhibitors. Confidence intervals of estimated ORs included the null value for most comparisons. The study confirmed that the differentiation between traditional NSAIDs and COX‐2 inhibitors is not a reliable tool for predicting cardiovascular risk associated with NSAIDs. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 23 references indexed in Scilit:
- The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarctionHeart, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Non‐Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial InfarctionBasic & Clinical Pharmacology & Toxicology, 2006
- Guidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiology and Drug Safety, 2005
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBMJ, 2005
- Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General PopulationCirculation, 2004
- Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research StudiesCirculation, 2003
- Use of nonsteroidal anti‐inflammatory drugs and the risk of first‐time acute myocardial infarctionBritish Journal of Clinical Pharmacology, 2002
- Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial InfarctionEuropean Heart Journal, 2000
- Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafilesStatistics in Medicine, 1995